Rani Therapeutics Holdings, Inc. - Class A (RANI) earnings
RANI earnings moved a median of -1.03% by the close. Quarterly and annual RANI reports and results, each read against the price at its own news timestamp. Back to the RANI overview →
21 measured RANI earnings events.
Where these RANI earnings landedvs 21 measured RANI earnings reactions
| Middle 50% of RANI earnings reactions | -2.89% to +1.54% |
|---|---|
| Median reaction (to close) | -1.03% |
| Measured reactions | 21 |
Point-in-time · zero look-ahead
Half of the 21 RANI earnings events with a measured close landed between -2.89% and +1.54%; 29% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Rani Therapeutics Holdin For: Jun 30 | SEC filing · Form 10-Q | +1.95% | +1.93% | |
| Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update | Press release | +1.95% | +1.93% | |
| Form 10-Q Rani Therapeutics Holdin For: Mar 31 | SEC filing · Form 10-Q | +4.67% | -8.27% | |
| Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition | Press release | +4.67% | -8.27% | |
| Form 10-K Rani Therapeutics Holdin For: Dec 31 | SEC filing · Form 10-K | -3.75% | -23.53% | |
| Form 10-Q Rani Therapeutics Holdin For: Sep 30 | SEC filing · Form 10-Q | +2.82% | +3.59% | |
| Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update | Press release | +2.82% | +3.59% | |
| Form 10-Q Rani Therapeutics Holdin For: Jun 30 | SEC filing · Form 10-Q | +1.67% | +1.54% | |
| Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update | Press release | +1.67% | +1.54% | |
| Form 10-Q Rani Therapeutics Holdin For: Mar 31 | SEC filing · Form 10-Q | +0.21% | -0.36% | |
| Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update | Press release | +0.21% | -0.36% | |
| Form 10-K Rani Therapeutics Holdin For: Dec 31 | SEC filing · Form 10-K | -1.45% | -1.60% | |
| Form 10-Q Rani Therapeutics Holdin For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -2.89% | |
| Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update | Press release | +0.00% | -2.89% | |
| Form 10-Q Rani Therapeutics Holdin For: Jun 30 | SEC filing · Form 10-Q | +0.00% | -3.95% | |
| Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update | Press release | +0.00% | -3.95% | |
| Form 10-Q Rani Therapeutics Holdin For: Mar 31 | SEC filing · Form 10-Q | -0.66% | -1.19% | |
| Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update | Press release | -0.66% | -1.19% | |
| Form 10-K Rani Therapeutics Holdin For: Dec 31 | SEC filing · Form 10-K | -4.78% | +0.00% | |
| Form 10-Q Rani Therapeutics Holdin For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -1.03% | |
| Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update | Press release | +0.00% | -1.03% |
Keep exploring
More RANI: analyst actions → · SEC filings → · RANI overview →